pembrolizumab
Akeso Begins Phase III Study of Anti-PD-1 Combo in Head and Neck Cancer
The firm is pitting a combination therapy targeting PD-1, VEGF, and CD47 against Keytruda in first-line advanced head and neck cancer.
Merck's Keytruda Added to Adjuvant Chemo Benefits Newly Diagnosed Endometrial Cancer Subpopulation
Premium
The combination did not benefit a biomarker unselected population, but those with mismatch repair-deficient tumors had extended disease-free survival.
Phase III data presented at the WCLC suggests the new VEGF and PD-L1 inhibitor could prolong progression-free survival versus Merck's anti-PD-1 blockbuster.
Merck Terminates Phase III Trials of Keytruda in Certain Cancers
The trials failed to show benefits compared to placebo during prespecified interim analyses.
Keytruda Sales Climb 16 Percent in Q2 as Merck Pursues New Oncology Candidates
The drugmaker updated investors on its three-pronged strategy to diversify its pipeline and not overly rely on its top-selling blockbuster checkpoint inhibitor.